Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fox

Showing results (981-990 of 1,012) with videos related to

Pageof 102
Sort By:
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
The New England Journal of Medicine|December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, David A Cairns, Adrian Bloor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
The New England Journal of Medicine|June 16, 2025
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Sean Girvan, David A Cairns, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 5, 2026
Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDSMark H Kuniholm, Gad Murenzi, Niharika Samala, et al.
Pageof 102

Showing results (981-990 of 1,012) with videos related to

Sort By:
Pageof 102
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
The New England Journal of Medicine|December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, David A Cairns, Adrian Bloor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
The New England Journal of Medicine|June 16, 2025
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Sean Girvan, David A Cairns, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 5, 2026
Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDSMark H Kuniholm, Gad Murenzi, Niharika Samala, et al.
Pageof 102